DetailsCategory: Proteins and PeptidesPublished on Thursday, 18 June 2020 09:51Hits: 112

June 17, 2020 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; JCR) announced today that the results of the phase 1 and 2/3 clinical trials of Agalsidase Beta BS I.V. Infusion [JCR] (JR-051), recombinant Agalsidase Beta, for Fabry disease have been published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders. This is JCRs first product for enzyme replacement therapy (ERT) for Lysosomal Storage Disorders (LSDs), also the first of the kind manufactured in Japan. Agalsidase Beta BS I.V. Infusion [JCR] has been launched since November 2018 as the first biosimilar for the treatment of rare diseases. A summary of the article is as follows.

Title: Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies

Digital Object Identifier: https://doi.org/10.1016/j.ymgme.2020.04.003

Summary The Phase 1 and 2/3 studies were conducted with the aim to verify clinical comparability of JR051 and an upfront biopharmaceutical (agalsidase beta). The results demonstrated that JR051 and agalsidase beta are comparable in terms of efficacy and safety.

Phase 1 study: 20 healthy adult male volunteers were administered JR-051 and agalsidase beta to confirm pharmacokinetic equivalence in a randomized, double-blind, parallel-group manner. The study demonstrated comparable pharmacokinetic profiles of JR-051 and agalsidase beta.

Phase 2/3 study: 16 patients with Fabry disease underwent treatment with agalsidase beta (1mg/kg, once every other week), then were switched to intravenous administrations of JR-051 (1 mg/kg, once every other week).

Efficacy: The 95% confidence intervals of the ratios of the GL-3 plasma concentrations (primary endpoint) during the agalsidase beta treatment, as well as those of Lyso-GL-3, to the respective plasma concentrations after 26 and 52 week-administrations of JR-051 were within pre-determined equivalence acceptability ranges.

Safety: No severe infusion associated reactions (IARs), such as anaphylactic shock, were observed. One IAR, commonly observed with the ERT for Fabry disease, was reported in a patient after JR-051 administration.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, Contributing towards peoples healthcare through pharmaceutical products drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

SOURCE: JCR Pharmaceuticals

Read this article:
Agalsidase Beta BS IV Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in...

Recommendation and review posted by Bethany Smith

Cancer can be a fatal disease, and the exact cause of cancer is still unknown. While many factors could lead to malignant disease, the reason is often based on estimation. The deadly disease affects both men and women alike, but a few types of cancer can be more dangerous in men than women. Genetics, lifestyle habits, and a few other factors make men more predisposed to certain types of cancer. Here are the most common types of cancer in men.

This is a no brainer as only men have the organ and so, women can't suffer from this cancer type. Every man should get a PSA test done after 50 years of age to check if their prostate is healthy. Prostate cancer can be a silent killer, and most often, an individual may not be aware unless one reaches the advanced stage.Mens Health Week 2020: From Cleaning Foot to Keeping Your Armpit Fresh, Here Are Five Personal Hygiene Habits Every Male Should Follow.

Tobacco use is more in men as compared to women which are a prime cause of lung cancer in men. That said, in recent times, there has been a rise in tobacco use in women. However, studies have shown that men are more at risk of lung cancer than women.Mens Health Week 2020: From Prostate Cancer To ED, Common Age-Related Health Problems In Men.

Bladder cancer is more common in men. A study published in the journal General Medicine where data was collected from both men and women who had bladder cancer showed that the male to female ratio was 2.2:1. The findings of the study also showed that the tumours were less aggressive and invasive in women as compared to men.

Did you know that men have a threefold higher risk of developing kidney cancer than women? Smoking, genetics and other occupational factors increase a man's chances of suffering from renal cell carcinoma. Plus, kidney cancer in men are characterised with larger tumours and are more aggressive.

While an equal number of men and women suffer from incidences of acute pancreatitis, chronic pancreatitis is more common in men. While men suffer from alcohol-related pancreatitis, in women, pancreatitis is more due to autoimmune diseases, gall stones and other factors.Men's Health Week 2020: Why Is Male Suicide Rate Higher? Know More About Mental Health Stigma.

Other forms of cancer like mouth and throat cancer and leukaemia are also more common in men than women. Men also tend to suffer from colorectal cancer, so clean eating and corrective lifestyle can save you big time!

(The above story first appeared on LatestLY on Jun 18, 2020 01:41 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).

View post:
Men's Health Week 2020: From Lung to Bladder, Types of Cancer that Can be More Dangerous in Men Than Women! - LatestLY

Recommendation and review posted by Bethany Smith

Photo courtesy of Getty Images

Michele Adams is quick to say, I dont want to throw anyone under the bus, but it took her being hit by a car for her thyroid disease to finally be diagnosed.

Adams has always been an active person, but for a few years, she had felt tired and had a constant tightness in her throat. She was diagnosed with post-nasal drip but did not feel relief after a year of treatment.

I thought this exhaustion, hoarse voice and lump in my throat were just my new normal, Adams said. Id accepted it, and I shouldnt have.

During this time, Adams went on a bike ride in northeastern New Jersey something she still does frequently. However, on this day, Adams was struck by a car as she was biking.

The incident resulted in an MRI scan. Adams was not seriously injured, but doctors noticed something unexpected. The scan revealed nodules in her lower neck, which suggested thyroid disease.

I now realize I had symptoms of a thyroid condition for years, Adams said. Id had it up to here with not feeling like myself. Once I had the MRI results, I knew to seek out a thyroid expert, and I found an endocrinologist.

What you probably do not know about your thyroid

Thyroid disease is more common than diabetes and heart disease, but more than half of Americans with thyroid disease are unaware, according to the American Association of Clinical Endocrinologists (AACE). This lack of awareness can endanger a persons health and well-being.

The thyroid is a butterfly-shaped gland located low in the front of the neck below the Adams apple. It produces thyroid hormones that influence almost every cell, tissue and organ in the human body.

Common signs of thyroid diseases include:

Cheryl Rosenfeld, D.O., is a thyroid expert and AACE member. Rosenfeld is also the physician who treated Adams thyroid disease.

If the thyroid does not function correctly, it can affect every possible aspect of a persons life, Rosenfeld said. Remember that thyroid conditions can cause changes in mental health, including depression. Ive also spoken to patients whove experienced an inability to concentrate, which seriously affected their performance at work.

Several disorders can arise if the thyroid produces too much hormone (hyperthyroidism) or not enough (hypothyroidism).

Other thyroid diseases include:

Undiagnosed thyroid issues can also place a person at increased risk for heart disease, osteoporosis, infertility and other serious conditions.

What to do if you are up to here with not feeling like yourself

Once I was placed on treatment for Hashimotos and hypothyroidism, my life changed completely, Adams said. My throat is no longer sore, and Im able to go out with my family or spend time at the gym without feeling completely drained of energy.

The first step to ensure your thyroid gland functions properly is to speak with a health care provider about your symptoms and whether a thyroid test is needed.

Anendocrinologistis aspecially trained doctor who is qualified to diagnose and treat hormone-related diseases and conditions, including thyroid cancer and all other diseases related to the thyroidgland.

Visitthyroidawareness.comto learn more about thyroid health.

Post Views: 165

Here is the original post:
'It Impacts Weight, Sleep and Mental Health': What You Need to Know About Your Thyroid Pasadena Weekendr - Pasadena Now

Recommendation and review posted by Bethany Smith

Atlantic Health System Cancer Care will continue its tradition of world-class medical education with its 2020 Annual Review in Oncology Virtual Symposium. The symposium, held virtually this year with free registration, will take place Saturday, June 27, 2020, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the Northeasts leading cancer centers will summarize the latest advances in oncology, which have recently been presented at international conferences. The diverse range of topics should be of interest to surgeons, medical and radiation oncologists and other physicians, nurses and allied health professionals.

Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System and principal investigator for the Atlantic Health Cancer Consortium, the only New Jersey-based National Cancer Institute Community Oncology Research Program (NCORP), will moderate.

Medical education in the era of COVID-19 is more important than ever, said Dr. Haigentz. Oncology education for physicians and other health care professionals has continued at Morristown Medical Center and Atlantic Health System, and we remain the go-to destination whether its in-person or online for oncology medical education with some of the nations top cancer researchers.

Sign Up for Flemington/Raritan Newsletter

Our newsletter delivers the local news that you can trust.

You have successfully signed up for the TAPinto Flemington/Raritan Newsletter.

Dr. Haigentz is an internationally known expert in lung and head and neck cancers, including thyroid cancer. He has served as lead or co-author on numerous studies, and is currently principal investigator at Atlantic Health System for 13 lung cancer studies and eight head and neck cancer clinical trials.

Dr. Haigentz will welcome symposium attendees, before introducing the presenters:

The programs learning objectives are for participants to be able to:

Atlantic Health System designates this live educational activity for a maximum of 4 AMA PRA Category 1 credits, Physicians should claim only the credit commensurate with the extent of their participation in the activity. Atlantic Health System is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.

The registration deadline is June 26, 2020. To register, email Danette.Clark@atlantichealth.org.

Read this article:
5 Key Areas of Cancer Research Presented by Thought Leaders at Annual Review in Oncology Virtual Symposium - TAPinto.net

Recommendation and review posted by Bethany Smith

At a time when leadership is needed to address the current COVID-19 pandemic and to tackle racial inequality and police brutality, the federal government is making changes that gamble with the lives of LGBTQ patients. Last week, the Trump administration finalized a rule to remove non-discrimination protections in health care and health insurance for LGBTQ persons, flying in the face of our ethical obligations as physicians to do no harm.

The prior rules outlined in Section 1557 of the Affordable Care Act established that it is illegal to discriminate on the basis of race, color, national origin, sex, age or disability in certain health programs and activities. Subsequent rules in 2016 expanded those protections regarding sex to ensure they encompass gender identity, thus providing for coverage of medically appropriate care for transgender individuals. These 2016 rules ensured that the law reflected the established science and policies of professional health organizations, including the American Medical Association and American Psychological Association.

This latest attempt by the Trump administration to eliminate protections for LGBTQ people relies on the false notion that sex is binary and immutable again demonstrates hostility towards LGBTQ persons, established science, and the practice of medicine. Under this new rule, a transgender person risks being refused routine preventive care, such as prostate cancer screening for a transgender woman and pap smears for a transgender man. Moreover, it threatens insurance coverage for needed gender affirming care such as hormone therapy and facial feminization surgery that research demonstrates can improve the health and well-being of transgender persons. As primary care physicians and providers of gender affirming care, we know that the risk of being denied these services or losing insurance coverage will cause significant harm to our patients.

If this discriminatory rule moves forward, it will also impact reproductive health care protections for individuals experiencing pregnancy and in need of termination, if the procedure violates the beliefs of the provider. Loss of these protections represents a barrier to care, and will lead to higher costs, and more importantly, a loss of dignity.

Transgender, non-binary, and gender diverse people already experience high rates of discrimination in health care. In the largest survey of transgender persons in 2015, 33 percent had at least one negative experience in a health care setting relating to their gender identity in the past year, and 23 percent did not seek care when needed, due to fear of being disrespected or mistreated as a transgender person. These experiences occur even more often for individuals of color and people with disabilities.

In a review of discrimination complaints submitted to the US Department of Health and Human Services, the most common issues involved individuals being denied care or insurance coverage because of gender identity or transgender status. These poor experiences include a transgender woman being denied a mammogram, a transgender man being refused screening for a urinary tract infection, an insurer not covering reproductive health care due to gender identity, and a transgender man being denied coverage for breast cancer genetic testing, despite the recommendation of his physician. These instances of discrimination are a stain on our profession and represent a failure to meet the needs of our patients. Ensuring access to health care and striving for optimal health for all persons are fundamental values of the medical profession and are long reflected in our ethics. The government should work to make it easier for all people to access health care, not more difficult.

This rule legitimizes unequal treatment of patients by clinicians, health care organizations, and insurers. In particular, it harms transgender individuals by providing cover for denial of needed care, and it represents a brutal blow to transgender persons of color, who already face greater health inequities related to the intersecting impact of racism and the anti-transgender sentiment expressed repeatedly by this administration. Such policy should not be permitted by the government, let alone proposed by it.

The administration claims to be protecting the moral and religious beliefs of health care professionals. But if providing care for LGBTQ persons violates health professionals beliefs, they are in the wrong profession.

Dr. Carl G. Streed Jr. is the research lead at the Center for Transgender Medicine and Surgery at Boston Medical Center. Dr. Jenny R. Siegel the medical director at the Center for Transgender Medicine and Surgery at Boston Medical Center.

Read more:
Trump administrations hostility toward LGBTQ lives will harm lives - The Boston Globe

Recommendation and review posted by Bethany Smith

On this page:BasicsBisphosphonatesRANKL InhibitorsHRTSERMsTSECAnabolic AgentsOther DrugsSupplements

Whether you have risk factors for developing osteoporosis or youve been diagnosed, you may wonder what the best avenues are for strengthening your bones. While theres no cure for this bone-thinning condition, with the right meds, you can see improvement and slash your risk of fractures.

Osteoporosis means porous bones. In short: Its a condition that occurs when you lose more bone mass than your body can make. Think of your bones as a bank account: You spend the first couple of decades of your life socking away bone (money) for retirement. When you reach age 30 or so, youll hit your peak bone massthe highest bone mass youll have in your lifetime. When youre a kid, a calcium-rich diet, exercise, and general good health yield healthy bone development.

If you skimped on any of the above (say, due to a childhood illness), your peak bone mass might be on the low side. Once you reach that retirement age (over 50), youll need to make some withdrawals; this is when you start losing bone mass naturally and bone formation slows.

If you didnt have a great peak bone mass to start with, you could get into trouble, leaving bones thin, brittle, and vulnerable to breaks. Certain risk factorssuch as being a postmenopausal woman or having a family history of osteoporosiscan also mean youll lose bone at a faster-than-normal rate.

The end goal of all osteoporosis treatments is to stabilize your bone densitymeaning, prevent you from losing additional bonerather than achieve a complete cure. These meds are designed to slow your bone loss, and in some cases, help make new bones, so yours are less vulnerable to fracture (breaking).

Thats important because fractures arent just painful they can be debilitating, leading to loss of mobility and independence, financial strain, and even death. The mortality rate a year after a hip fracture is about 22 percent. Yet, osteoporosis causes a staggering number of bone breaks a year: 1.5 million to be exact, according to research in the Journal of the American Medical Association.

To answer that, lets start with what actually constitutes osteoporosis. The condition is often diagnosed when you have a bone density scan, a test that measures your bone mineral density (BMD).

The most common BMD test is a dual-energy X-ray absorptiometry or bone densitometry referred to as a DXA or DEXA scan. It checks the mineral levels in your bones, comparing your level to that of a 30-year-old of the same gender. The idea is to see how far your bone density has deviated since then. Heres how to read your results, known as a T-score:

If youve suffered a fracture, your doctor will likely do a bone density scan to see if osteoporosis is at play. The scan is also routinely given to women starting at age 65 (at risk women can start at 60) and to men starting at 70 years old.

Your doctor will also determine how likely you are to fracture a major bone within the next 10 years via a Fracture Risk Assessment Tool (FRAX). If you have osteopenia and a low risk of fracture, you probably wont be treated with an osteoporosis drug. Instead, the recommendation is to make lifestyle changes to improve, or at least stabilize, your bone density. What kinds of tweaks are we talking about? These may include:

However, if youre diagnosed with osteopenia and have a high risk of fracture, your physician may start you on osteoporosis meds to slow down your bone loss before it becomes osteoporosis. Medications arent always a given though. A person who is diagnosed relatively young with no history of fractures and is otherwise healthy may not need meds just yet.

A few drug classes for osteoporosis that work in different ways to prevent fracture and a treatment plan may include one of the following types of drugs:

This family of meds give your natural bone production a chance to play catch-up by slowing or stopping resorption, when bones break down and release minerals such as calcium into your blood. They home in on and inhibit osteoclasts, the cells that do the breaking down. Antiresorptive drugs include:

Youve probably heard of Fosamax or Boniva (or the Boniva generic ibandronate). Theyre part of this drug class the most commonly prescribed for osteoporosis. Bisphosphonates work by slowing down those osteoclasts, giving your osteoblasts (the bone-building cells) a chance to get ahead. Examples include:

Most drugs come with some risk of side effects, and bisphosphonates are no exception. The most common side effects of bisphosphonates are:

There is a side effect from Fosamax called osteonecrosis of the jaw (loss of blood supply to this bone). Its a risk with all bisphosphonates, but its rare and usually seen in people receiving high doses of the meds during cancer treatments. Another less common side effect is atypical femoral fracture; (yes, an osteoporosis med can actually cause a bone break). Long-term use is linked to breaks in the upper thigh area. Zoledronic acid side effects can also include flu-like symptoms, but theyre temporary.

To reduce the risk of the more serious side effects, current osteoporosis treatment guidelines for bisphosphonates call for reassessing a patients fracture risk after three to five years. If your risk of fracture is low-to-moderate after treatment, you may be able to take a break from the drugs; those who are still high risk can remain on bisphosphonates for up to 10 years.

These injections work by neutralizing RANKL, a protein thats necessary for osteoclasts to do their job breaking down bone. Theyre given via injection every six months, depending on the brand, for up to 10 years. Example include:

RANKL injections can also lead to atypical fractures, and that risk is even greater if you suddenly stop treatment. A study in the journal Osteoporosis International found a five percent increase in multiple vertebral fractures after halting the osteoporosis treatment injection.

HRT cuts down on fragility fractures by 20 to 35 percent, studies have shown, but because of its potential health risks (pulmonary embolism, cardiovascular issues, and breast cancer are just a few), its considered a last resort treatment for osteoporosis alone and is reserved for women who are experiencing both menopause symptoms and osteoporosis. Side effects can include:

HRT is approved for women in the form of daily oral tablets and transdermal patches that are applied daily or weekly.

SERMs arent hormones, so they dont carry the same risks as traditional HRT, but this class of drugs does act similar to estrogen in the body by reducing menopause systems and fortifying your bones and preventing fracture, particularly in the spine.

Its a good option for women who are dealing with both menopause symptoms and osteoporosis, but have a high risk of breast cancer that eliminates HRT as an option. SERMs are taken as a daily tablet. One example is Evista (raloxifene), a daily oral tablet approved for women. Evitas most common side effects are:

This type of drug, like Duavee (conjugated estrogens/bazedoxifene) combines estrogen with a SERM to help with severe menopause symptoms such as hot flashes and boost bone mineral density. Research has shown it can increase both spine and hip density after 12 months. Its a daily tablet thats taken orally. Side effects can include:

Because TSEC contains estrogen, it carries some of the risks of HRT.

These are your bone builders. This osteoporosis drug class is designed to stimulate osteoblasts, the cells that beef up bone formation. Theyre typically reserved for more severe cases of osteoporosis where the risk of fracture is very high. Anabolics include:

The most common side effects of these osteoporosis treatment injections are:

The newest bone maker on the block, romosozumab-aqq, is an anti-sclerosin monoclonal antibody approved for postmenopausal women with high risk of fracture. It comes with a risk of cardiovascular issues, so if youve had a heart attack or a stroke within the past year, this is not an ideal drug. Teriparatide and abaloparatide are synthetic versions of parathyroid hormone, which regulates calcium, essential for strong bones.

While worries about side effects may give you pause about filling your prescription for osteoporosis meds, its important to remember this: The benefits of preventing a fracture (and all that comes with it) win out over the risks of taking these meds, according to guidelines from the Endocrine Society published in The Journal of Endocrinology & Metabolism.

Its not widely done, but theres evidence that pairing an antiresorptive with an anabolic agent may yield better results than giving one drug alone. One study in the Journal of Bone and Mineral Research showed combining the bisphosphonate zoledronic acid with the anabolic teriparatide boosted bone mineral density in the spine and hip more than either drug alone.

In an analysis of seven studies, research in the BMJ Open found that a combo of the two drug classes greatly improved bone mineral density of the hip and spine more quickly than an anabolic agent alone. Some doctors will also give an anabolic first (in severe cases) and prescribe a bisphosphonate to maintain your newly formed bone mass.

While bisphosphonates and anabolic agents are the most common osteoporosis medications, some drugs that are used to treat other conditions that can also have a positive effect on bone density.

Youve probably heard steroids are bad for bones. Its true; long-term use of corticosteroids (synthetic drugs that are similar to cortisol, a hormone your body produces) deteriorates bone mineral density, causing osteoporosis. But low doses of anabolic steroids (synthetic versions of the male hormone androgen) may have the opposite effect, stimulating bone growth and reducing osteoporosis pain from fractures, according to research in Clinical Calcium. However, theres limited data to know the long-term side effects of anabolic steroids.

This used to be a malaria medication. How can that possibly help your bones? Hydroxychloroquine is antirheumatic, meaning its used to treat rheumatoid arthritis (RA), lupus, Sjgen syndrome, etc. Researchers discovered those treated with Plaquenil had higher bone mineral density than those who werent. Its not FDA approved for osteoporosis and comes with a rare, but serious risk of eye damage in high doses. More common side effects include:

This is another type of bisphosphonate given via IV infusion that slows down bone loss, but its primarily used to treat bone damage from Pagets Disease (a chronic disease that causes deterioration of bone tissue) and certain types of cancer, as well as hypercalcemia (high levels of calcium in blood caused by calcium). Its an option for osteoporosis patients, but zoledronic acid has proved better for fracture prevention.

Right now, there are no natural supplements that experts recommend in lieu of FDA-approved osteoporosis drugs. If youve been searching the internet for that, youve probably come across info on strontium, a trace element, for osteoporosis.

There is some scientific basis on this one. A study found that postmenopausal women who took two grams of strontium ranelate every day for three years suffered 37 percent fewer spinal fractures compared to women taking a daily placebo pill.

Theres also a strontium ranelate-based drug (Protelos) approved in Europe, but not here in the US. (Its associated with some serious side effects such as pulmonary embolism and heart attacks.) So, should you take an over-the-counter version of the mineral, such as strontium citrate or strontium chloride, to strengthen your bones? Not so fast. These are not the same as strontium ranelate, and theres no evidence they work.

What about OTC estrogen pills? Phytoestrogens, plant-based versions of the hormone such as soy and flaxseed, have some limited data behind them to show that they may help slow bone loss. But physicians say not enough to replace your prescribed medication. Phytoestrogens in your diet may be better at preventing low bone density than treating osteoporosis.

No one drug stands out as the safest; all medications have side effects. Youll have to weigh the pros and cons of each with your physician to find the right fit for you. Typically, bisphosphonates are well tolerated and have been shown to be safe to take for up to 10 years, which is why theyre the first line of treatment for osteoporosis.

Theres no cure for osteoporosis, but you can strengthen bones and reduce the risk of fracture by taking medications and making lifestyle changes. These include: boosting your calcium and vitamin D intake, doing weight-bearing exercises at least three days a week, drinking less alcohol (no more than one to two drinks a day), and if youre a smoker, quitting.

No, osteoporosis drugs are not a lifelong commitment. You can take bisphosphonates for up to 10 years, but the latest osteoporosis guidelines suggest reassessing a patients bone density between three and five years, and, if possible, taking a break from the drugs. Bisphosphonates linger in your bones after you stop taking them, so you have some built-in protection. RANKL agents such as Prolia can be used up to 10 years, while anabolic agents can only be given for up to two years.

The risk of suffering a fracture is far greater than incurring some of the most serious side effects of medication. One in two women over age 50 will fracture a bone and fractures can be extremely painful and debilitating. Need more convincing? Consider this stat from a New York Times article: For every 100,000 women taking bisphosphonates, fewer than three will have osteonecrosis of the jaw, and only one will suffer an atypical femoral fracture. But 2,000 will have avoided an osteoporotic fracture.

Visit link:
What Are Your Osteoporosis Medication Options? - HealthCentral.com

Recommendation and review posted by Bethany Smith

Mikel Kelly: There's a lot going on in the world, but at the end of the day, nothing means 'as much as my own health'

On Monday, June 15, I celebrated the 20th anniversary of the day I was told by a physician's assistant at Kaiser Permanente, following a biopsy conducted by that very same man (at Mother Joseph Plaza annex, next door to St. Vincent Hospital), that I had tested positive in five out of six samples taken for prostate cancer.

It was June 15, 2000, and even though it seemed like every other famous man over 50 was announcing to the world that they had this same brand of cancer, it completely floored me. I was 52 and otherwise very healthy.

It was almost embarrassing how little I knew about this disease, but because I had to sort through the various "treatments" (which included, oddly enough, doing nothing) I quickly learned a whole lot about it.

First of all, I discovered I was lucky. Of all the kinds of cancer out there, prostate cancer is one of the most common but even more important, one of the slowest moving. People who contracted breast cancer, pancreatic cancer, esophageal cancer and others soon learned that time is of the essence, and in most cases, the earlier discovered the better.

My most immediate challenge was to learn as much about the disease as possible and then choose the kind of attack I was going to employ.

My cousin Dennis, in Seattle, was a few months ahead of me in his own fight with the disease, and he quickly rounded up a huge bundle of magazine articles, medical reports and journals on the subject and sent them to me. He had chosen the therapy in which they plant a number of radioactive seeds in the walnut-size organ.

There was also a lot of support for the "normal" radiation treatment, where they blast you down there in the groinal region with the invisible rays 35 times every week day for seven weeks (more about this approach later).

The do-nothing option was never appealing to me. Maybe if I was 75 or 80 at the time, I'd consider it because they say it's such a slow-growing cancer it's not that hard to outlive it. Usually, the medical folks tell you, you'll die of something else entirely.

No, I selected what they called "the gold standard" the surgery where they cut a hole in you (eerily similar to the slice one makes when cleaning a trout) and remove the whole enchilada. My own surgery was of the "nerve sparing" variety, meaning the doctor I settled on, Chris Mershon, would as delicately as possible try to extract the prostate from the web of nerves surrounding it which, in turn might allow me to retain sexual function, no small item to a 52-year-old fellow. It was a success, I was told, and I was further advised that I came through it with good margins.

But (you knew there would be a "but" didn't you?), almost exactly five years later, my PSA (the prostate specific antigen, the number all prostate cancer sufferers live and die by) began to rise again.

Unfortunately, at exactly that moment in time, the company I worked for announced that it would no longer include Kaiser Permanente in the insurance choices we were offered -- so, with the help of my doctor, I picked a new physician to handle my care, a Legacy urologist, Dr. Bruce Lowe, and together we sorted out the options and settled on radiation therapy as my next adventure.

Unlike the prostatectomy I underwent back in 2000, the radiation is the treatment that really kicked my butt. Though the actual treatment, in the opening weeks of 2006, went smoothly enough, the after-effects in subsequent years were significant. As time went by, I lost all sexual function, and have had a continual battle with urinary incontinence. Then, this February I was subjected to an even more serious indignity that no one had ever mentioned up to then: blood clots in the bladder that had me climbing the walls of the Good Samaritan ER until they finally poked a drain in me to take the pressure off. Apparently, this blood clotting thing is not uncommon in cases where radiation has been used.

So, while everybody else was staying home and staying safe, I was making numerous and repeated visits to see health professionals, my urologist in Portland, the surgeon in Seattle who installed an artificial sphincter in me two years ago to control my peeing (which was damaged during my ER adventure and no longer was working) AND my brand new medical oncologist (Dr. Julie Graff and her team) at the OHSU Knight Cancer Center, where I began a new round of treatment because my PSA had decided to swing back up again.

This latest attack on my cancer is a ferocious brand of hormone treatment, called androgen deprivation therapy in which I get a shot in the belly fat every three months, along with a fairly aggressive "oral chemo" that involves me taking a couple of horse pills every day exactly two hours after breakfast and at least an hour before lunch. The side effects of this round of treatment is significant, though not yet intolerable. They mostly consist of fierce hot flashes about every hour, along with a tendency to poop out quickly during uphill walks.

So, this is why I'm kind of losing touch with all that's going on out there in the real world the COVID-19 pandemic, the Black Lives Matter protests going on in pretty much every community of any size, the financial tailspin that everybody but the very wealthiest in our nation is in and the utter lack of leadership from the White House.

All of those things worry me a lot. Not as much as my own health, maybe, but still a lot.

Stay safe out there. And if you're a guy and there's any history of prostate cancer in your family, get it checked. If you do, you might be lucky enough to hang around a few more years, like me.

Mikel Kelly, a former editor with Pamplin Media Group, retired from Community Newspapers a little over four years ago. He no longer chases fire trucks and police sirens, but he does have a tendency to send in these "observations" to us.

You count on us to stay informed and we depend on you to fund our efforts.Quality local journalism takes time and money. Please support us to protect the future of community journalism.

Read this article:
Opinion: This month my cancer turned 20, but I am still standing - Pamplin Media Group

Recommendation and review posted by Bethany Smith

You open your microwave and discover a cup of coffee you reheatedyesterday. Names escape you. And wherefor the 1,000th timedid you leave those dang AirPods? It's normal to be forgetful every once in a while, but if you find yourself battling multiple brain farts daily, it may be time to dig deeper to uncover the cause. Don't panic: Chronic forgetfulness doesn't always mean Alzheimer's disease. In fact, there are a whole host of reasons your memory might be stalling. Find out if one of these could be causing your brain drain.

1You're taking a medication that has memory side effects.

"If you're concerned with your memory, one of the first things to do is to review your medication list with your physician," says Lauren Drag, Ph.D., a neuropsychologist at Stanford Health Care. Several prescription and OTC drugs can mess with your memory, she notes. Topping that list are anticholinergics, which are drugs that interfere with a neurotransmitter in your brain called acetylcholine. Antihistamines like Benadryl, reflux drugs like Zantac, muscle spasms treatments like Flexiril, and depression drugs like Paxil and Elavil are all considered anticholinergics. Other medications to watch for include certain blood pressure drugs, sedatives like Valium, and some pain medications. If you suspect your treatment is to blame for your memory blips, ask your doctor if there's an alternative worth considering.

2You're struggling with depression.

When you're in a mental funk, it's hard to focus on what's in front of youwhich makes recalling it later virtually impossible. Depression may actually reshape certain parts of your brain, says Drag. "Research suggests that it can be associated with changes in the size and functioning of brain regions that are important to skills such as memory, the speed at which we think, attention, and problem-solving ability."

3You're drinking too much.

You know booze muddles your mind while you're drinking, but it can also make heavy drinkers forgetful after they've dried out. "Interestingly, research has shown that sobriety can lead to a temporary worsening in memory and thinking, as you go through a detox period," says Drag. Some peoplemainly life-long alcohol abusersmight never get their sharpness back. But most people can expect the fog of forgetfulness to eventually lift, says Drag, though it can take anywhere from weeks to months.

RELATED: Are you drinking too much in quarantine?

4Your tension level is through the roof.

Stress distracts your brain when it should be memorizing information. That's why a phone number you've just been told can escape you before you even have time to pull the phone out of your pocket and dial.In the short-term, "someone who is feeling anxious can have difficulty following a conversation because he or she is ruminating over a worrisome topic," says Drag. And chronic, severe stress is even worse. "It can have a significant impact on the brain, presumably through long-term exposure to hormones that are released during periods of stress," she explains. Even the everyday hassle of managing household bills and busy schedules can chip away at your memory skills. "Juggling multiple tasks at once, staying up late to finish tasks, not exercising and not eating wellall of these factors can increase forgetfulness," says Drag.

5You have a chronic or undiagnosed health issue.

Any ailment that affects your brain's blood supplylike diabetes, high blood pressure, or high cholesterolcan cause mental blocks. "A variety of health conditions, such as hypothyroidism, vitamin deficiencies, and hormone imbalances can also cause memory problems," says Drag. "In older adults in particular, urinary tract infections can cause sudden and temporary confusion." She recommends checking with your primary care physician for a physical to rule out these common causes and ensure there's nothing to worry about. In some cases, a simple vitamin supplement will help restore your brainpower.

6You're just plain exhausted.

Just because you're logging 8 (or more) hours under the covers doesn't mean you're getting good quality rest. Research has shown that people who spend less time in deep sleep have more trouble with memory. The good news? Sometimes all it takes is a quick power napeven if you snooze for as little as 6 minutesto give your brain a boost. If you're feeling abnormally tired despite your siestas, get a thorough checkup. "Sleep apnea, for example, can deprive the brain of oxygen and lead to changes in the blood supply to the brain which over time can negatively impact memory and thinking abilities," says Drag.

RELATED: 11 Best Multivitamins for Women in 2020

7You're just getting older.

As you age, your brain might show signs of wear and tearjust as your skin gets more wrinkled and your joints become creakier. Alzheimer's becomes much more likely after 65, but mild forgetfulness is even more common. So don't instantly freak out if you find yourself struggling to learn new skills, or to think of the word you want to use in a sentence. "The most common complaints I see from older adults are that they have difficulty coming up with words and walk into a room and forget why they are there," says Drag. "These lapses can certainly be normal."

How do you know if your forgetfulness has moved past what's normal? If your memory lapses start impacting your daily life, it's worth getting checked out. "An isolated incident of missing an exit or turning the wrong way when driving a new route isn't unusual," says Drag, "But if you're frequently getting lost while driving, particularly in familiar locations, talk with your doctor." In the meantime, exercising, making smart food choices, and surrounding yourself with a strong support network may help you stay sharper longer.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Read the original post:
7 Commons Reasons for Forgetfulness That Have Nothing to Do With Alzheimer's - Prevention.com

Recommendation and review posted by Bethany Smith

The novel coronavirus has added a lot of terms to our collective vocabulary. The latest is antigens, and though these proteins may sound similar to antibodies and both will be key to test as doctors learn more about COVID-19 they actually play very different roles in the body and the course of the disease. POPSUGAR asked experts for a quick breakdown of these two terms and what they mean for the strategy moving forward.

Contrary to what it might sound like, antibodies actually protect your body! Your immune system produces these little Y-shaped proteins to defend you against invader cells (pathogens). "An antibody is the immunoglobulin (protein) produced by the immune system," Habib Sadeghi, DO, a physician and integrative medicine specialist in Los Angeles, told POPSUGAR.

Fun fact: antibodies are produced by certain lymphocytes. A doctor can check your antibody levels in your blood. For COVID-19, "doctors look for two kinds of antibodies to SARS CoV-2 to determine exposure: IgM antibodies that develop early in an infection and IgG antibodies that appear after levels start to drop about four weeks in," said Dr. Sadeghi. The latter would in theory allow you to develop some level of long-term immunity, but experts still aren't sure if that's the case.

Antigens are not produced by the body. "An antigen is any substance that induces a response from the immune system," Dr. Sadeghi explained. This can range from a toxin to simply a foreign substance. Remember the pathogens we just mentioned? Those invader cells? Antigens are part of pathogens the part that triggers the antibodies to spring into action.

From there, "an antibody is capable of binding with the antigen and neutralizing it," Dr. Sadeghi said. This is typically how your body fights off an infection.

Antigen tests are the latest offering in the fight against COVID-19, designed to help manage the large number of tests needed to detect active cases. Antigen testing is cheaper than nasal swab testing, and blood results come back faster.

"The antigen test looks for actual pieces of protein of the virus itself, where the antibody test looks for evidence of a person's immune system response to being infected," William Kimbrough, MD, of One Medical, told POPSUGAR. "This means that the antigen test is identifying people with active infections (similar to what the more broadly available PCR swabs do), where the antibody tests look for people who have been previously infected."

Your doctor can help you determine which test is right for you. Just remember: a positive result on the antibody test does not necessarily mean you have immunity, so please, keep social distancing and following CDC guidelines until there's a safe and effective vaccine.

Follow this link:
Confused About Antigen Testing For COVID-19? Here's How It Differs From Antibody Testing - POPSUGAR

Recommendation and review posted by Bethany Smith

If you're looking for a more consistent sleep aid that helps you fall asleep and stay asleep, family medicine physician Robert Rountree, M.D., says magnesium is the way to go: "Melatonin does one thing very well, which is to provide a specific signal to the brain that it is time to initiate the sleep process. It isn't so great for maintaining sleep," he tells mbg.*"Magnesium helps to calm down the central nervous system, which helps to prepare the brain to turn off and also to keep it functioning at a calmer level throughout the night.*" Since magnesium is a mineral and not a hormone, there's less concern over taking it every day, though you should always talk to your doctor before introducing a new supplement into your routine.

This ability to promote a longer-lasting state of relaxation is why mindbodygreen chose magnesium as the workhorse of our new sleep supplement, magnesium+. We worked with Rountree on the formulation, which includes 120 mg of magnesium glycinate as well as other sleep promoters like jujube and pharmaGABA, to help you fall asleep faster, stay asleep longer, and wake up feeling refreshed.*

See the article here:
Melatonin vs. Magnesium: The Difference Between The Sleep Aids, Explained - mindbodygreen.com

Recommendation and review posted by Bethany Smith

The killing of George Floyd, a Black man who died as a Minneapolis police officer knelt on his neck, has triggered a global conversation about racism, anti-racism, racial bias, police brutality, how non-Black people understand their privilege, and how to be an effective and genuine ally.

But for many interracial couples, conversations about race and privilege have always been part of their lives.

Insider spoke to two couples in interracial relationships on how they met, fell in love, and how race has influenced the way they navigate the world together.

Advertisement

Chelsie, 30, and Bedford, 35, told Insider they didn't think much about race when they first started dating. While Bedford is Black and of Haitian descent and Chelsie is white, they both grew up in Utah which is 90.7% white, and both come from a Christian background. Bedford said that might have influenced their conversation on race as a couple. The only big question on Chelsie's mind when they first met was how Bedford would react to her having a son, which had been a dealbreaker with other dates.

"A little after we had started dating that someone had made a comment to me a little along the lines of 'Well, your kids will never look like you,'" Chelsie told Insider.

"I was like 'Isn't that crazy?' and he was like 'That's actually not crazy. I've had quite a few people break up with me for that reason. Just because their kids will never have blonde hair and blue eyes, their genetics don't necessarily shine through in that way.'"

Since getting married in 2014, they've had three more kids, and now work together as content creators.

We were all meeting at a restaurant and I got pulled over about a block from the restaurant, my family's there, her family's there, we were all together for a birthday.

Because I know that, more often than not, police officers are scared when they pull people over, and some of them are scared of me. So coming in and my wife wanting to fight, scream, yell, be emotional, I'm like "No, this is going to be a whole lot worse if we don't keep our heads."

Bedford: The riots are happening, and we're aware of it. It's disappointing that the riots are happening, but only because riots occur only when people aren't being heard. I understand people are frustrated with things being broken, but at the end of the day, it's been hundreds of years of a demographic, of a group of people who have not been heard.

We had a conversation and she said "Are you scared?" and I'm not anymore scared than I've ever been and I think that was kinda a turning point for her when she realized "this is the unsettledness that you feel all the time, this is how you feel."

Chelsie: I told Bedford, "My fear with the riots is it just makes the police more afraid of you." Because we were talking one time and Bedford said, "You know, it's hard as a police officer in this situation if someone's walking towards you, how much time do you give them to find out what their intentions are?" And that's what's scary for me because I was like, "Well, you have good intentions."

Bree Koegel, 31, met CJ, 35, her now-husband and soon-to-be father of their first child, through their work as fitness models for Wilhelmina.

"This isn't the first interracial relationship I've been, and Bree had known that," CJ said. "I think between her and I, there was this lack of us going into some of those deep conversations because I think we both automatically felt we stood on the same principles."

I look at it from my perspective and said, "Well, if I have things I need to unlearn, better believe the people above me in my family have things that they need to unwind too because they've gone through a lot of stuff in this world too."

I've watched after my conversations and how I saw certain things being handled. It's simple things that I saw like getting into my dad's car on the way to the store and when he turns the car on, it was on a station of a history channel based off of learning about the inequalities of the Black community.

It's difficult to look at your family and see things that you know need to be changed. There's some people in my family who didn't go to my sister's wedding based off of the fact that they didn't want her to marry a Black guy.

Bree: He was like, "I don't know why this is just hitting me different. I know that this happens, and I know that we've seen injustice caught on film before, but this feels different."

Then to see George Floyd days later, and the whole world's reaction, all of a sudden it didn't feel taboo or aggressive to post about it. It was like, "Oh no, you know what? This isn't just a problem inside our relationship to address, this is a problem the world needs to address. If we can expose our conversation to the world, and help them move this along, then by all means with these, our platform to do so."

I think these conversations with me now being empowered and me now, not really giving a cr-p about offending somebody, it's going to change the way that we engage in this world, for the better. And it's going change the way we engage as parents for the better. As scary as everything has been, I'm excited for the revolution, because of what it means for our child.

Some public health experts support protests in spite of the coronavirus risks: 'White supremacy is a lethal public health issue'

A mother and daughter who just graduated from the same medical school are starting their careers as doctors at the same institution

Continued here:
Interracial couples on how they're talking about race, love, and Black Lives Matter: 'The conversation took a - Business Insider India

Recommendation and review posted by Bethany Smith

A five-bedroom, two-bathroom house in Queensland,

Australia, is currently on the market for just under

$600,000, but theres a reason why its so cheap.

According to the real estate listing

posted by PRD Real Estate, the house

which is just a few minutes from the

beach is experiencing subsidence.

Translation? Its sinking.

In an interviewwith realestate.com.au,

marketing agent Danny ODonnell said that he

was surprised by how many people were interested

in the beach house despite the subsidence.

I spent four days straight answering calls. Each

time I hung up, I had seven new voice messages.

By Saturday morning Id had over 100 text messages

and phone calls and 58 emails. It was crazy.

When ODonnell hosted an open house

for the literal sinking ship, he was

shocked to find more than 200 people

lined up to tour the property.

Within days, PRD Real Estate had

offers that ranged from $550,000 to

$675,000, well above the asking price.

The owners of the house ended up accepting

a cash offer from a local buyer for $647,000

More here:
This 5-bedroom house is deeply discounted but there's a catch - Yahoo Lifestyle

Recommendation and review posted by Bethany Smith

Logo of World Anti-Doping Agency. (Photo Credit: Getty Images)

The battle against the coronavirus pandemic has been a long drawn out one, with the end not really in sight. However, there was positive news in the fight when new data from the UK-led clinical trial known as RECOVERY showed that giving low doses of the generic steroid drug dexamethasone to patients reduced death rates by around a third among those with the most severe cases of infection.

The results, which are being described as a major breakthrough, has caused study authors to suggest that the drug should immediately become the standard medicine being prescribed for patients who are being treated in hospitals for the pandemic.

However, the steroid Dexamethasone is banned by the World Anti-doping Agency, a ruling which earlier in the year caused serious headaches to India's javelin thrower Davinder Singh Kang who failed a dope test for the said steroid.

According to the WADA rules on their website, "All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes."

The list of the banned glucocorticoids includes:

Betamethasone

Budesonide

Cortisone

Deflazacort

Dexamethasone

Fluticasone

Hydrocortisone

Methylprednisolone

Prednisolone

Prednisone

Triamcinolone

The Asian Games bronze medal-winning javelin thrower Davinder Singh Kang had claimed that the root cause was a sore throat and is confident of being cleared in the disciplinary hearing.

I had severe sore throat and before Indian GP 5 last year, I consulted a private physician in Patiala after taking permission from team management. The doctor gave me two medicines Moxitas 500 and beta dexamethasone. The dope test result is because of this medicine, Kang was quoted as saying by PTI.

I also declared these two medicines in the dope sample collection form when people from Nada took the samples. I have not gained any advantage in my performance from these medicines. So, there is no fault on my part. I will explain this to the Nada and I hope I should be cleared of this doping charge, the 31-year-old had said.

Dexamethasone is a low-cost steroid and is available widely, including in India. It is known to be used to treat inflammations and conditions such as arthritis, blood disorders, lupus, allergic reactions and skin conditions. India has not officially recommended its use so far.

Also Read: Another Delay for Olympics Should be Considered, Says Tokyo 2020 Board Member

Dexamethasone, which has been used since the early 1960s to treat a wide range of conditions such as rheumatoid arthritis and asthma, is a prescription medication that is available as an oral tablet, oral solution, eye drops, and eardrops.

The oral tablet is used to treat conditions that cause inflammation, conditions related to immune system activity and hormone deficiency. It belongs to a class of drugs called steroids.

It is a low-cost steroid and is available widely, including in India. It is known to be used to treat inflammations and conditions such as arthritis, blood disorders, lupus, allergic reactions and skin conditions. India has not officially recommended its use so far.

https://pubstack.nw18.com/pubsync/fallback/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2&categories=5d95e6d7340a9e4981b2e102&query=anti+doping+laws%2Ccoronavirus%2Ccoronavirus+medicine%2Ccoronavirus+pandemic%2CDavinder+Singh+Kang&publish_min=2020-06-13T21:45:00.000Z&publish_max=2020-06-16T21:45:00.000Z&sort_by=date-relevance&order_by=0&limit=2

Read more from the original source:
Steroid Dexamethasone That Could be a Life-saver Against Covid-19 is Prohibited by WADA - News18

Recommendation and review posted by Bethany Smith

Cancer Gene Therapy Market size is expected to exceed USD 2.5 billion by 2025. Rising cancer prevalence across the globe will positively impact the cancer gene therapy market growth.Some major findings of the cancer gene therapy market report include:

Increasing mortality rates due to cancer has created a huge demand for cancer gene therapies

Technological advancements in the biotechnology sectors has led to developments in the cancer gene therapy that are being now preferred by healthcare professionals

Regulations for cancer gene therapy are quite structured and stringent in developed economies such as the U.S. and Germany while the regulatory scenario is still ambiguous in emerging economies

Cancer gene therapy industry is still in developing phase and yet to witness numerous growth opportunities in the coming years

Some of the major industry players include: Sirion Biotech, Vigene Biosciences, bluebird bio, Ziopharm, Cellectis, Cobra, Finvector, Uniqure, Sarepta Therapeutics, Caribou among others. These industry players adopt several strategic initiatives to maintain their market position.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/763

Technological advancements in the biotechnology sector have led to developments and innovations in cancer gene therapy. Recently developed cancer therapies have been incorporated with genetically modified genes that blocks the growth of tumor. Moreover, efficient PCR technology and isothermal amplification technologies have been introduced that transformed the way of detecting mutations in the genes. Moreover, introduction of CRISPR gene editing tools have modified the process of developing gene therapy. Hence, advancements in technology has ensured availability of advanced cancer gene therapy that will boost the industry growth. However, high cost of cancer gene therapy may impede its demand, thereby restraining the industry growth to certain extent.

Type segment of cancer gene therapy market includes ex-vivo and in-vivo. In-vivo segment is projected to experience around 22% growth throughout the analysis timeframe owing to various advantages associated with it. In-vivo gene therapy involves direct delivery of therapeutic gene into the target cell and has shown effective results in treatment of cancer. The viral vectors that are delivered utilizing in-vivo gene therapy help in inhibiting the activity of tumor inducing genes and has also shown positive results during clinical trials. Aforementioned factors will elevate the segmental growth.

Get In-depth table of contents @ https://www.gminsights.com/toc/detail/cancer-gene-therapy-market

Products of cancer gene therapy include viral vectors and non-viral vectors. Viral vectors segment was valued over USD 310 million in 2018. Viral vectors are highly preferred during gene transfer process as they have showcased high transfection efficiency. Viral vectors possess safety profile as compared to other vectors. Moreover, viral vectors expresses the desired antigen in accurate conformation enhancing the immune system.

End-users of cancer gene therapy are biopharmaceutical companies, research institutes and others. Biopharmaceutical companies segment accounted for around 48% revenue share in 2018 and is expected to experience exceptional growth in the forthcoming years. Companies such as Novartis and Roche are developing cancer gene therapies that have high adoption of viral as well as non-viral vectors, thereby proving beneficial for the segmental growth. These companies also conduct clinical trials that raises the demand for vectors, hence fostering the segmental growth.

China cancer gene therapy market will experience over 26% CAGR throughout the forecast years. Significant country growth can be attributed to the rising awareness regarding the availability of advanced therapies for treating cancer. Furthermore, increasing government initiatives and funds motivate the researchers and scientists for carrying out extensive research activities associated with cancer gene therapy that will positively influence the country growth. Above mentioned factors coupled with increasing prevalence of cancer will further stimulate the industry growth.

Cancer gene therapy industry is dominated by few major players. Cancer gene therapy industry is still in the developing phase, therefore, players involved in thie market focus on integrating advanced technology to promote developments in the therapies. The players also implement certain strategic initiatives such as merger, acquisitions and product launches for acquiring competitive advantage. For instance, in 2013, Celgene and bluebird bio collaborated to introduce innovations in gene therapies. Such collaborations will provide both the companies to gain competitive advantage over others.

View original post here:
Cognizance into Cancer Gene Therapy Market and it's growth prospects - Cole of Duty

Recommendation and review posted by Bethany Smith

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

The rest is here:
Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D - Endpoints News

Recommendation and review posted by Bethany Smith

Dublin, June 18, 2020 (GLOBE NEWSWIRE) -- The "Nucleic Acid Isolation and Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Precision Medicine), End User (Academic) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global nucleic acid isolation and purification market is projected to reach USD 4.8 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 8.9% during the forecast period.

The major factors driving the growth of the market include increasing R&D activities as well as technological advancements and increasing automation. However, the high cost of automated instruments is expected to hinder the growth of the market.

The instruments segment will grow at the highest rate during the forecast period.

On the basis of product, the nucleic acid isolation and purification market are segmented into kits, reagents, and instruments. In 2019, kits were the largest product segment in the market. Growth in this market can be attributed to the continuous focus of key market players on developing and launching new and advanced kits. However, the instruments segment is expected to grow at the highest rate during the forecast period.

By type, the plasmid DNA isolation and purification segment accounted for the largest share of the nucleic acid isolation and purification market in 2019.

On the basis of type, the global nucleic acid isolation and purification market are segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. The plasmid DNA isolation segment accounted for the largest share of the nucleic acid isolation and purification market in 2019. The large share of this market segment can be attributed to the wide use of purified plasmid DNA in a variety of downstream applications, such as PCR, sequencing, expression of proteins, gene therapy, and transfection.

The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2025).

North America accounted for the largest share of the nucleic acid isolation and purification market in 2019. Significant R&D spending in biotechnology and pharmaceutical companies, the large size of the biotechnology industry, technological advancements, and government support in the region are the key factors driving the growth of the nucleic acid isolation and purification market in North America. On the other hand, the Asia Pacific is projected to register the highest growth during the forecast period. This large share can be attributed to factors such as the increasing number of genomic projects and increasing R&D investments by pharmaceutical & biotechnology companies in this region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Nucleic Acid Isolation and Purification Market Overview 4.2 North America: Nucleic Acid Isolation and Purification Market, by Product (2019) 4.3 Geographical Snapshot of the Nucleic Acid Isolation and Purification Market

5 Market Overview 5.1 Market Dynamics 5.1.1 Drivers 5.1.1.1 Increasing R&D Activities 5.1.1.2 Technological Advancements and Increasing Automation 5.1.2 Restraints 5.1.2.1 High Cost of Automated Instruments 5.1.3 Opportunities 5.1.3.1 High Scope of Growth in Emerging Economies 5.1.3.2 Improving Regulatory and Reimbursement Scenario 5.1.3.3 Molecular Diagnostics and Personalized Medicine 5.1.4 Trends 5.1.4.1 Impact of the Covid-19 Pandemic 5.1.4.2 Increase in Government Funding

6 Nucleic Acid Isolation and Purification Market, by Product 6.1 Introduction 6.2 Kits 6.2.1 Kits Were the Largest Product Segment in the Market in 2019 6.3 Reagents 6.3.1 Reagents Segment to Grow at a Steady Rate During The Forecast Period 6.4 Instruments 6.4.1 Automated Instruments Enable a Faster, Cleaner, and More Consistent Nucleic Acid Extraction Process

7 Nucleic Acid Isolation and Purification Market, by Method 7.1 Introduction 7.2 Column-Based Isolation and Purification 7.2.1 Column-Based Isolation and Purification Was the Largest Segment in the Market in 2019 7.3 Magnetic Bead-Based Isolation and Purification 7.3.1 Magnetic Bead-Based Isolation and Purification Segment to Register the Highest CAGR During the Forecast Period 7.4 Reagent-Based Isolation and Purification 7.4.1 Reagent-Based Isolation and Purification Segment to Register Steady Growth During the Forecast Period 7.5 Other Isolation and Purification Methods

Story continues

8 Nucleic Acid Isolation and Purification Market, by Type 8.1 Introduction 8.2 Plasmid Dna Isolation and Purification 8.2.1 Plasmid Dna Isolation and Purification Accounted for the Largest Share of the Market 8.3 Total Rna Isolation and Purification 8.3.1 Total Rna Isolation and Purification Segment to Register Steady Growth 8.4 Genomic Dna Isolation and Purification 8.4.1 Genomic Dna Isolation is the First Step in Genetic-Based Tests 8.5 Messenger Rna Isolation and Purification 8.5.1 Messenger Rna Isolation and Purification is Mainly Used in the Study of Gene Expression and Transcriptomics 8.6 Circulating Nucleic Acid Isolation and Purification 8.6.1 Clinical Applications to Drive the Market for Circulating Nucleic Acid Isolation and Purification 8.7 Microrna Isolation and Purification 8.7.1 Microrna Kits Provide Rapid Isolation and Purification of Rna Molecules from Samples 8.8 Pcr Cleanup 8.8.1 Time-Consuming Laboratory Procedures to Limit the Growth of this Market During the Forecast Period 8.9 Other Nucleic Acid Isolation and Purification Types

9 Nucleic Acid Isolation and Purification Market, by Application 9.1 Introduction 9.2 Diagnostics 9.2.1 Diagnostic Applications Form the Largest and Fastest-Growing Segment in the Market 9.3 Drug Discovery & Development 9.3.1 Ngs Benefits Drug Discovery Applications in Various Therapeutic Areas 9.4 Personalized Medicine 9.4.1 Rising Incidence of Cancer and Increasing Research and Funding to Drive the Market for this Segment 9.5 Agriculture & Animal Research 9.5.1 Favorable Funding Scenario to Support Market Growth 9.6 Other Applications

10 Nucleic Acid Isolation and Purification Market, by End-user 10.1 Introduction 10.2 Hospitals & Diagnostic Centers 10.2.1 Availability of Genetic Tests and Rising Focus on Personalized Medicine in Hospitals to Drive Market Growth 10.3 Academic & Government Research Institutes 10.3.1 Increase in Research Intensity to Drive the Usage of Nucleic Acid Isolation and Purification Systems 10.4 Pharmaceutical & Biotechnology Companies 10.4.1 Increasing Number of Research Projects in Genomics and Related Areas is Expected to Drive the Market 10.5 Contract Research Organizations 10.5.1 Contract Research Organizations Are Expected to Register Steady Growth During the Forecast Period 10.6 Other End-users

11 Nucleic Acid Isolation and Purification Market, by Region 11.1 Introduction11.2 North America11.2.1 US11.2.1.1 Government and Private Funding to Support Market Growth in the Us11.2.2 Canada11.2.2.1 Demand for Nucleic Acid Isolation and Purification in Canada is Increasing Primarily Due to Growing Investments in Genomics11.3 Europe11.3.1 Germany11.3.1.1 Germany is the Largest Market for Nucleic Acid Isolation and Purification in Europe11.3.2 UK11.3.2.1 Government Support for Research in the Form of Investments, Funds, and Grants to Support Market Growth11.3.3 France 11.3.3.1 High Cancer Burden in France to Drive Market Growth 11.3.4 Roe 11.4 Asia-Pacific 11.4.1 China 11.4.1.1 China to Register the Highest Growth in the Nucleic Acid Isolation and Purification Market in APAC 11.4.2 Japan 11.4.2.1 Japan to Register Steady Growth During the Forecast Period 11.4.3 India 11.4.3.1 Strong Growth Trends in the Pharmaceutical & Biotechnology Industries to Drive the Market in India 11.4.4 Roapac 11.5 Rest of the World 11.5.1 Latin America 11.5.1.1 to Prevent Cancer Mortality, the Brazilian Government Recommends Screening Programs for Breast and Prostate Cancer 11.5.2 Middle East & Africa 11.5.2.1 Lack of Infrastructure for Research to Hamper the Growth of the Naip Market in the Middle East & Africa

12 Competitive Landscape 12.1 Introduction 12.2 Market Evaluation Framework 12.3 Revenue Analysis of Top Market Players 12.4 Competitive Scenario 12.4.1 Collaborations & Agreements 12.4.2 Product Launches & Approvals 12.4.3 Acquisitions 12.4.4 Expansions

13 Company Evaluation Matrix and Company Profiles 13.1 Company Evaluation Matrix 13.1.1 Market Share Analysis 13.2 Competitive Leadership Mapping (Overall Market) (2019) 13.2.1 Stars13.2.2 Emerging Leaders 13.2.3 Pervasive Players 13.2.4 Emerging Companies

14 Company Profiles 14.1 Qiagen N.V. 14.2 Thermo Fisher Scientific 14.3 F. Hoffman-La Roche AG 14.4 Promega Corporation 14.5 Agilent Technologies 14.6 Bio-Rad Laboratories 14.7 Danaher Corporation 14.8 GE Healthcare 14.9 Illumina 14.10 Merck Kgaa 14.11 Takara Bio, Inc. 14.12 New England Biolabs 14.13 Zymo Research 14.14 Norgen Biotek 14.15 Omega Bio-Tek, Inc. 14.16 Other Companies 14.16.1 Genaxxon Bioscience GmbH 14.16.2 3B Blackbio Biotech India Ltd. 14.16.3 Invitek Molecular GmbH 14.16.4 Biovision 14.16.5 Analytik Jena AG

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/abjwtq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
Global Nucleic Acid Isolation and Purification Market (2020 to 2025) - High Scope of Growth in Emerging Economies - Yahoo Finance UK

Recommendation and review posted by Bethany Smith

Latest Gene Therapy Market report evaluates the impact of Covid-19 the industry, involving potential opportunity and challenges, drivers and risks and market growth forecast based on different scenario. Global Gene Therapy industry Market Report is a professional and in-depth research report on the worlds major regional market.

This Gene Therapy Market report will help the business leaders to detail better field-tested strategies and settle on educated choices to improved benefit

Get Exclusive Sample Report on Gene Therapy Market is available at https://inforgrowth.com/sample-request/6405074/gene-therapy-market

Top Players Listed in the Gene Therapy Market Report areBluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene.

Gene Therapymarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Gene Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into Ex vivo, In Vivo.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6405074/gene-therapy-market

The report introduces Gene Therapy basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Gene Therapy Market for the coming few years have also been included in the report.

In the end, Gene Therapyreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Gene Therapymarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6405074/gene-therapy-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to read the rest:
Gene Therapy Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Bluebird Bio, Sangamo, Spark Therapeutics, Dimension...

Recommendation and review posted by Bethany Smith

Dublin, June 15, 2020 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking2.1. Introduction2.2. Gene therapy partnering over the years2.3. Most active Gene therapy dealmakers2.4. Gene therapy partnering by deal type2.5. Gene therapy partnering by therapy area2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals3.1. Introduction3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers4.1. Introduction4.2. Most active Gene therapy dealmakers4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/6xcnxy

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Gene Therapy Global Partnering Terms and Agreements Directory of Deals by the World's Leading Healthcare Companies from 2014-2020 - GlobeNewswire

Recommendation and review posted by Bethany Smith

INTRODUCTION Biologics represent one of the fastest growing classes of therapeutic molecules in modern healthcare. As per an article published in January 2020, the annual global market of biologics is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals.

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" - https://www.reportlinker.com/p05483804/?utm_source=GNW , Considering the necessity to bypass gastric metabolism, biologics are mostly designed for administration via parenteral routes. In fact, majority of such therapies are formulated for intravenous delivery and are usually administered in a clinical setting (hospitals / infusion centers). However, this scenario is cost intensive and is known to be associated with medication adherence related concerns. In this context, the subcutaneous route of drug delivery offers a number of benefits, including self-medication and life cycle management options. Although the pharmacokinetic profiles of intravenous and subcutaneous formulations are different, studies have demonstrated that the latter formulations are preferred by end users (patients and healthcare providers), offering substantial cost saving opportunities.

Presently, the subcutaneous delivery option is being investigated for a number of clinical candidates across different phases of development. Moreover, several approved therapeutic products, which are currently available in intravenous dosage forms, are also being reformulated and evaluated for subcutaneous administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been shown to result in highly viscous formulations when reformulated for subcutaneous delivery. In order to address this particular challenge, many companies have developed / are developing a number of novel technology platforms to facilitate the delivery of viscous drug formulations. Similar innovations are gradually facilitating a shift to subcutaneous delivery, primarily driven by the demand for self-administrable therapeutics. In fact, there are several self-medication solutions, equipped with a variety of user-friendly features, available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed high adoption, enabled substantial reductions in healthcare expenses (incurred by patients), and improved therapy adherence. In this regard, the rising incidence of chronic clinical conditions (which are characterized by the need for frequent medication) and the ongoing efforts of therapy / device developers engaged in this field, are anticipated to drive the growth of the subcutaneous biologics market in the coming years.

SCOPE OF THE REPORTThe Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following: A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route, along with information on approval year, phase of development, type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players. A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable). An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s). An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. Also, the study includes a detailed benchmark analysis of the technology developers based in North America and Europe, highlighting the primary advantage(s) offered by their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration. Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook. An analysis of collaborations and partnership agreements inked by the subcutaneous formulation technology developers since 2011; it includes details of deals that were / are focused on subcutaneous formulation technologies, which were analyzed on the basis of year of agreement, type of agreement, and upfront and milestone payments. An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows: Large volume wearable injectors: Stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force). Autoinjectors: Usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual). Pen injectors: Usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose). Needle-free injection systems: Stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others). Drug reconstitution systems: Usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others). Prefilled syringes: Barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL). Implants: Stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information. A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industrys evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential of the subcutaneous biologics, technologies and drug delivery systems market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] phase of development (approved, preregistration & phase III and phase II & phase II/III)), [B] type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), [C] target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences) Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies) Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals) David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices) Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio) Poonam R Velagaleti (Co-Founder, i-novion) Michael Hooven (Chief Executive Officer, Enable Injections) Frederic Ors (Chief Executive Officer, Immunovaccine Technologies) Patrick Anquetil (Chief Executive Officer, Portal Instruments) Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) David Heuz (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market over the next decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the subcutaneous biologics, technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction to the various types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecule structure, immunogenicity and stability. The chapter also highlights different types of biologically derived products that are currently being developed by various stakeholders in this industry. It further discusses the challenges associated with the parenteral route of drug delivery, specifically, those related to the traditional intravenous (infusion) route. Further, the chapter features a discussion on the different routes of administration, specifically focusing on the subcutaneous route, highlighting its advantages and associated limitations.

Chapter 4 includes information on over 450 subcutaneous biologic drug candidates that are currently approved / being developed. It features a comprehensive analysis of marketed and clinical-stage biologics based on the approval year, phase of development type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players.

Chapter 5 is a collection of case studies on the leading subcutaneous biologics, in terms of the annual global sales. Each case study includes drug / therapy specifications, their respective mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).

Chapter 6 provides a list of subcutaneous formulation technologies that are currently available / being developed by various firms in this domain. The chapter highlights key features of each technology and provides information on their developers. It also features an analysis based on the type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).

Chapter 7 features a three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. It also includes a benchmark analysis of technology developers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration

Chapter 8 includes elaborate profiles of key technology developers, featuring overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the subcutaneous formulation technologies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2011. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants. It includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable injectors, by stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force), [B] autoinjectors, by usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual), [C] pen-injectors, by usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose), [D] needle-free injection systems, by stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others), [E] drug reconstitution systems, by usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others), [F] prefilled syringes, by barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL), and [G] implants, by stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. As large volume wearable injectors, pre-filled syringes, needle-free injectors and autoinjectors represent the most novel and advanced types of devices, we have also provided a comprehensive product competitiveness analysis of these products taking into consideration the supplier power (based on size of employee base) and product specifications.

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industrys evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

Chapter 12 presents an informed estimate of the current and future opportunity in the subcutaneous biologics, technologies and drug delivery systems market, highlighting the likely growth of the market till the year 2030. It also includes future sales projections of various subcutaneous biologic drug candidates that are currently being evaluated by different players. The chapter presents a detailed market segmentation on the basis of phase of development (approved, preregistration & phase III and phase II and phase II/III), type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors, drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics.

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuz (Communication Leader, MedinCell).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05483804/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:
Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 - Yahoo Finance UK

Recommendation and review posted by Bethany Smith

Many age-related diseases such as liver fibrosis, atherosclerosis, diabetes and osteoarthritis have been partly attributed to cellular "senescence," a zombie-like state in which cellsstop proliferating but remain alive. Could CAR-T therapy, which involves genetically editing patients' own immunecells, treat those diseases by targeting senescent cells?

Researchers at Memorial Sloan Kettering Cancer Center haveset out to answer that question. They designed CAR-T cells that target a protein called urokinase plasminogen activator receptor (uPAR) on the surface of senescent cells. The CAR-T cells worked in mouse models of liver and lung cancers and liver fibrosis, the team reported in Nature.

Senescence is a double-edge sword, the studys co-corresponding author Scott Lowe explained in a statement. Cells in this state play an important role in wound healing and cancer deterrence. But if they linger for too long, they can cause chronic inflammation, which itself is a cause of many diseases.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

Clearing accumulated senescent cells has emerged is a new field in drug research called "senolytics." For example, Californias Unity Biotechnology is working on several senolytic drugs to treatage-related diseases, including one incollaboration with Chinas Ascentage Pharma to address a range of eye disorders.

But for CAR-T cells to work as senolytics, the Memorial Sloan Kettering researchers first needed to identify an antigen on senescent cells that the CAR (chimeric antigen receptor) couldtarget. The two CAR-T treatments on the market now, blood cancer drugs Kymriah from Novartis and Yescarta from Gilead Sciences, are directed at the antigen CD19 on cancer cells.

By screening molecules on the surface of cells in both mice and humans, the Memorial Sloan Kettering team found that uPAR was highly expressed on senescent cells but was mostly absent in normal tissue.

After designinguPAR-specific CAR-T cells, Lowe's team decided to test them in premalignant cells that typically undergo senescence. In mouse models of liver and lung cancer, the team found that the CAR-T cells successfully cleared these premalignant senescent cells. The treatment significantly prolonged survival in the lung cancer models.

In a mouse model of liver fibrosis marked by the accumulation of senescent cells in the liver, treatment with the uPAR-directedCAR-T cells significantly reduced liver scarring when compared to control animals. Blood levels of liver enzymes also dropped, indicating improved liver function. Similar results were observed in fibrosis induced by non-alcoholic steatohepatitis, or NASH, a liver condition many biopharma companies have tried to tackle but failed.

RELATED:Gene-edited T cells to treat diabetes inch closer to clinical trials

Several other research groups are investigating T-cell approaches for treating inflammatory diseases. Scientists at the University of Pennsylvania developed chimeric "autoantigen" receptor (CAAR) T cells that target rogue antibodies against the muscle-specific kinase to treat myasthenia gravis. A team at the University of Tennessee has investigated a CAR-T treatment that targets the harmful B cells behind lupus.

Recently, scientists from the Seattle Childrens Research Institute and the Benaroya Research Institute transformed CD4 T cells into cells with immunosuppressive properties with the goal of controlling the autoimmune response in Type 1 diabetes.

The Memorial Sloan Kettering team is hopeful their uPAR-directed senolytic CAR-T cells hold potential for treating several senescence-related diseases associated with aging. They're now planning to test the therapy in atherosclerosis, diabetes and osteoarthritis.

Read more:
Treating age-related diseases with a CAR-T that targets 'senescent' cells - FierceBiotech

Recommendation and review posted by Bethany Smith

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Global Genetic Modification Therapies market sizes from 2015 to 2024, along with CAGR for 2018-2024Market size comparison for 2017 vs 2024, with actual data for 2017, estimates for 2018 and forecast from 2019 to 2024Global Genetic Modification Therapies market trends, covering comprehensive range of consumer trends & manufacturer trendsValue chain analysis covering participants from raw material suppliers to the downstream buyer in the global Genetic Modification Therapies marketMajor market opportunities and challenges in forecast timeframe to be focusedCompetitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic managementComprehensive company profiles of the key industry players

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Gain detailed insights on the Genetic Modification Therapies industry trendsFind complete analysis on the market statusIdentify the Genetic Modification Therapies market opportunities and growth segmentsAnalyse competitive dynamics by evaluating business segments & product portfoliosFacilitate strategy planning and industry dynamics to enhance decision making

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

IntroductionResearch MethodologyExecutive SummaryMarket Overview4.1 Introduction4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.2.4 Challenges4.2 Porters Five Force AnalysisGenetic Modification Therapies Market, By Platform TechnologyGenetic Modification Therapies Market, By Delivery TechnologiesGenetic Modification Therapies Market, By End-User IndustryGenetic Modification Therapies Market, By DiseaseGenetic Modification Therapies Market, By GeographyCompetitive InsightsCompany Profiles11.1 4D Molecular Therapeutics11.1.1 Company Overview11.1.2 Product/Service Landscape11.1.3 Financial Overview11.1.4 Recent Developments11.2 Abeona Therapeutics11.2.1 Company Overview11.2.2 Product/Service Landscape11.2.3 Financial Overview11.2.4 Recent Developments11.3 Beam Therapeutics,11.3.1 Company Overview11.3.2 Product/Service Landscape11.3.3 Financial Overview11.3.4 Recent Developments11.4 Casebia Therapeutics,11.4.1 Company Overview11.4.2 Product/Service Landscape11.4.3 Financial Overview11.4.4 Recent Developments11.5 Editas Medicine,11.5.1 Company Overview11.5.2 Product/Service Landscape11.5.3 Financial Overview11.5.4 Recent Developments11.6 Fate Therapeutics,11.6.1 Company Overview11.6.2 Product/Service Landscape11.6.3 Financial Overview11.6.4 Recent Developments11.7 GE Healthcare,11.7.1 Company Overview11.7.2 Product/Service Landscape11.7.3 Financial Overview11.7.4 Recent Developments11.8 Hitachi Chemical Advanced Therapeutics,11.8.1 Company Overview11.8.2 Product/Service Landscape11.8.3 Financial Overview11.8.4 Recent Developments11.9 Immunocore,11.9.1 Company Overview11.9.2 Product/Service Landscape11.9.3 Financial Overview11.9.4 Recent Developments11.10 Jivana Biotechnology,11.10.1 Company Overview11.10.2 Product/Service Landscape11.10.3 Financial Overview11.10.4 Recent Developments

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read the rest here:
Genetic Modification Therapies Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole...

Recommendation and review posted by Bethany Smith

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Membrane Chromatography Market by Product, Technique, Operation Mode, End User - Global Forecast to 2025" - https://www.reportlinker.com/p05339881/?utm_source=GNW 5% during the forecast period. The major factors driving the growth of this market are the benefits offered by membrane chromatography over conventional chromatography methods, increasing biopharmaceutical R&D, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes.

The consumables segment commanded the largest share of the market in 2019.On the basis of product, the membrane chromatography market is segmented into consumables and accessories.The capsules, cassettes, and cartridges segment accounted for the largest share of the membrane chromatography consumables market in 2019.

The large share of this segment is primarily attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing, lab-scale production, and process development.

The affinity membrane chromatography segment is expected to register the highest growth in the global membrane adsorbers market during the forecast period.On the basis of technique, the membrane adsorbers market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography.The affinity membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period.

The increasing use of protein A chromatography for antibody purification and immobilized metal affinity membrane chromatography for the purification of proteins are supporting the growth of this segment.

The pharmaceutical and biopharmaceutical companies segment commanded the largest share of the membrane chromatography market in 2019.Based on end user, the membrane chromatography market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes.In 2019, the pharmaceutical and biopharmaceutical companies segment accounted for the largest market share.

The large share of this segment is attributed to the increased R&D in pharmaceutical and biopharmaceutical companies and increased production of biologics.

The bind-elute segment is projected to register the highest growth in the global membrane adsorbers market during the forecast period.The bind-elute membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period. The increasing demand for viruses in the production of attenuated vaccines and gene therapy and the development of high-performance bind-elute membrane chromatography solutions (with a higher binding capacity to capture larger targets such as adenovirus and lentivirus and virus-like particles) are the key factors driving the growth of this segment.

The Asia Pacific market is projected to register the highest growth in the global membrane chromatography market during the forecast period.The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The growing biopharmaceutical industry, significant investments by key market players, increasing government support, and developing R&D infrastructure are the key factors driving the growth of this segment.

In-depth interviews were conducted with chief executive officers (CEOs), marketing directors, other directors, and executives from various key organizations operating in the membrane chromatography market. By Respondent Type: Supply Side (70%) and Demand Side (30%) By Designation: Managers (55%), CXOs (20%), and Executives (25%) By Region: North America (50%), Europe (20%), APAC (20%), and the RoW (10%)

The membrane chromatography market comprises major players such as Sartorius AG (Germany), Danaher Corporation (US), Merck Millipore (Germany), Thermo Fisher Scientific Inc. (US), and 3M Company (US). The study includes an in-depth competitive analysis of these key players in the membrane chromatography market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:The market study covers the membrane chromatography market across various segments.It aims at estimating the market size and the growth potential of this market across different segments based on product, technique, end user, and region.

The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall membrane chromatography market and its subsegments.This report will help stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.

The report will also help stakeholders to understand the pulse of the market and provide information on the key market drivers, restraints, opportunities, and challenges.Read the full report: https://www.reportlinker.com/p05339881/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
The membrane chromatography market is estimated to grow from USD 198 million in 2020 to USD 408 million by 2025, at a CAGR of 15.5% - GlobeNewswire

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking

2.1. Introduction

2.2. Gene therapy partnering over the years

2.3. Most active Gene therapy dealmakers

2.4. Gene therapy partnering by deal type

2.5. Gene therapy partnering by therapy area

2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals

3.1. Introduction

3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers

4.1. Introduction

4.2. Most active Gene therapy dealmakers

4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction

5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/mam3lf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Original post:
Global Gene Therapy Partnering Terms and Agreements Directory 2014-2020 - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

The research reports on Emerging Gene Therapies Market report gives detailed overview of factors that affect global business scope. Emerging Gene Therapies Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Emerging Gene Therapies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1854862

Top Company Profile Analysis in this Report

AmgenGilead SciencesNovartisSanofiGlaxoSmithKlinePfizer

and more

Emerging Gene Therapies Market Report provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development. The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Additionally, the report provides a background to the CRISPR patent litigation, a key factor within the gene editing company landscape. It provides profiles of six companies developing gene editing platforms, considers the gene therapy interests of the main pharmaceutical companies, and discusses current regulatory trends in the development of gene therapies.

Emerging Gene Therapies Market Report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Scope of this Report- What are the key emerging products within the gene therapy landscape? Which companies have the strongest pipeline of innovative products? How will gene editing disrupt existing gene therapy products? What are the regulatory trends for emerging gene therapies? What are the interests of pharmaceutical companies within the field?

Reasons to buy this Report- Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector. Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver. Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

Single User License: US $ 2995

Get FLAT 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1854862

Table of Contents in this Report-1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 102.1 Gene Therapy Definitions 102.2 Report Coverage the Emerging Gene Therapy Pipeline 112.3 History of Gene Therapy 122.4 Limitations of Gene Transfer 132.5 The Development of Targeted Gene Editing 132.6 Overview of Gene Editing Platforms 132.6.1 Zinc Fingers (1996) 132.6.2 Transcription Activator-Like Effectors (2011) 142.6.3 The CRISPR/Cas System (2013) 152.6.4 Effectors for Targeting Domains 192.6.5 Comparison of Gene Editing Systems 192.6.6 Summary of Gene Editing Systems 192.7 Overview of In Vivo Gene Therapy 212.7.1 Editing is Dependent on Cell Type, Stage, and Repair Pathway 212.7.2 Delivery 212.7.3 Emerging Safety Concerns with Editing Platforms 242.7.4 Editing Products are Reliant on the Target Cells Cycle Stage and DNA Repair Machinery 272.7.5 Advantages of Gene Editing over Gene Transfer 282.7.6 Integration into Safe Harbor Sites 282.7.7 The Increasing Complexity of Gene Therapy 302.7.8 Summary of In Vivo Gene Therapy 313 Gene Therapy Near Term Product Pipeline 333.1 Leber Congenital Amaurosis 333.1.1 Unmet Need 333.1.2 Molecular Genetics 333.1.3 Luxturna (Voretigene neparvovec) 333.1.4 Editas Medicine: EDIT-101 353.1.5 Trial Design 363.1.6 EDIT-101 and Off-Target Effects 373.1.7 The Potential Advantage of EDIT-101 is the Longevity of its Therapeutic Effect 373.1.8 Summary LCA 383.2 Choroideremia 383.3 Hurler Syndrome (MPS I) 393.3.1 Key Clinical Studies 403.3.2 Regenex: RGX-111 403.3.3 Sangamo Therapeutics: SB-318 403.4 Hunter Syndrome (MPS II) 413.4.1 Unmet Need 413.4.2 Sangamo Therapeutics: SB-913 413.4.3 Immusoft Corporation: Cell Therapy 433.5 Sanfilippo Syndrome (MPS III) 433.5.1 Lysogene: LYS-SAF302 433.6 Summary MPS Disorders 443.7 Hemophilia 443.7.1 Hemophilia A 463.7.2 Summary Hemophilia A 503.7.3 Hemophilia B 513.7.4 Summary Hemophilia B 533.8 Hemoglobinopathies 543.8.1 Beta Thalassemia: Unmet Need 543.8.2 Beta Thalassemia: Molecular Genetics 553.8.3 Sickle Cell Disease: Unmet Need 563.8.4 Sickle Cell Disease: Molecular Genetics 563.9 Cellular Therapies for Hemoglobinopathies 573.9.1 Blue Bird Bio: BB-305 (LentiGlobin) 573.9.2 Sangamo: ST-400 603.9.3 CRISPR Therapeutics: CTX-001 613.9.4 Summary: Cellular Therapies for Hemoglobinopathies 623.10 Duchenne Muscular Dystrophy 633.10.1 Unmet Need 633.10.2 Molecular Genetics 633.10.3 ExonDys 51 Sarepta Therapeutics 643.10.4 Solid BioSciences: SGT-001 663.10.5 Exonics Therapeutics: CRISPR Approach 673.10.6 Summary Duchenne Muscular Dystrophy 684 Competitive Landscape 694.1 Regulatory Considerations for Developing Gene Therapy Products 694.1.1 Product Characteristics 694.1.2 Clinical Study Design for Gene Therapy Products 694.1.3 Disease specific guidance 704.1.4 Reimbursement and Payment 714.1.5 Summary Regulatory Considerations 724.2 Intellectual Property CRISPR/Cas 724.2.1 Licensing, Exploitation, and MPEG Pool 744.3 Company Analysis: Gene Editing Companies 754.3.1 Sangamo Therapeutics 754.3.2 CRISPR Therapeutics 794.3.3 Casebia Therapeutics 814.3.4 Editas Medicine 824.3.5 Intellia Therapeutics 844.3.6 Homology Medicines 864.4 Company Analysis: Pharma 874.4.1 Amgen 874.4.2 Gilead Sciences 874.4.3 Novartis 874.4.4 Sanofi 884.4.5 GlaxoSmithKline 884.4.6 Pfizer 885 Appendix 895.1 References 895.2 Report Methodology 98

and more

Read more:
2020 Emerging Gene Therapies Market Report- Trends within the Technological, Clinical, Regulatory and Competitive Landscape - 3rd Watch News

Recommendation and review posted by Bethany Smith

INTRODUCTION Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain.

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-Viral Transfection Reagents and Systems Market, 2020-2030" - https://www.reportlinker.com/p05915358/?utm_source=GNW Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma (USD 2.1 million) and Luxtruna (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.

SCOPE OF THE REPORTThe Non-Viral Transfection Reagents and Systems Market, 2020-2030 report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features: A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location. An insightful 2X2 representation, highlighting the competitiveness analysis of non-viral transfection system developers captured in our database, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered). An analysis highlighting potential strategic partners segregated based on likelihood of entering into collaboration with non-viral transfection system developers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, type of vector and company size. An analysis of the big pharma players engaged in this domain, featuring a heat map based on parameters, such as type of initiative, type of therapy and target therapeutic area. An analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population. An in-depth analysis of close to 14,000 patents related to non-viral transfection systems that have been filed / granted since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. A detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, cost per transfection, share of non-viral systems within the transfections market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the future opportunity across [A] non-viral transfection systems (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the markets evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names): George Eastwood (Vice-President of Business Development, Kytopen) Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified..

RESEARCH METHODOLOGYThe research, analysis and insights presented in this report are backed by a deep understanding of insights gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the non-viral transfection systems market in the mid to long term.

Chapter 3 provides an overview of transfection and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It highlights different methods of transfection (such as viral and non-viral), with a brief outline of various viral vectors (AAV, adenoviral, lentiviral, retroviral and others), chemical methods (lipoplexes, polyplexes, lipoplexes and others) and physical methods (electroporation, gene gun, sonoporation, magnetofection and others) used in transfection.

Chapter 4 provides an overview of various types of non-viral transfection systems including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.

Chapter 5 provides a detailed competitiveness analysis of the companies offering non-viral transfection systems, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).

Chapter 6 includes detailed profiles of prominent transfection reagent developers, electroporation-based transfection system developers and other non-viral delivery system developers, featuring a brief overview of the company, its financial information (if available), recent developments and an informed future outlook.

Chapter 7 features an insightful analysis, highlighting potential strategic partners, based on likelihood of entering into collaboration with non-viral transfection system developers, taking into account several parameters, such as type of therapy, pipeline strength, pipeline maturity, company size and type of vector.

Chapter 8 highlights the activity of top ten big pharma players in this domain, featuring a heat map based on parameters, such as such as type of initiative, type of therapy and target therapeutic area.

Chapter 9 provides an analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to non-viral transfection systems, since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 presents a detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

Chapter 12 presents a detailed market forecast, highlighting the future potential of the non-viral transfection systems market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] non-viral transfection methods (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with George Eastwood (Vice-President of Business Development, Kytopen) and Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05915358/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Excerpt from:
Non-Viral Transfection Reagents and Systems Market, 2020-2030 - Yahoo Finance

Recommendation and review posted by Bethany Smith